2015
Current and emerging modalities for detection of cardiotoxicity in cardio-oncology
Khouri MG, Klein MR, Velazquez EJ, Jones LW. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. Future Cardiology 2015, 11: 471-484. PMID: 26235924, PMCID: PMC5558528, DOI: 10.2217/fca.15.16.Peer-Reviewed Original ResearchConceptsEarly detectionLife-saving cancer therapyCurative-intent therapyCancer-specific mortalityCancer-specific survivalCardiovascular risk factorsDetection of cardiotoxicityFunctional capacity testingNovel adjuvant therapyDegree of cardiotoxicityAdjuvant therapyCardiovascular morbidityCardiovascular mortalityCardiovascular dysfunctionCardiovascular injuryBlood biomarkersRisk factorsEarly preventionCancer treatmentCardiotoxicityTherapyMortalityCancer therapyDiagnostic toolInjury
2010
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, investigators F. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 2010, 375: 1173-1181. PMID: 20170948, DOI: 10.1016/s0140-6736(09)62100-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlbuminuriaAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCardiovascular DiseasesCreatinineDisease ProgressionDiureticsDouble-Blind MethodDrug CombinationsFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionKidney Failure, ChronicMaleMiddle AgedRisk FactorsConceptsChronic kidney diseaseKidney diseaseAmlodipine groupHydrochlorothiazide groupCardiovascular eventsCombination therapyHigh riskChronic kidney disease progressionEnd-stage renal diseaseFixed-dose combination therapyAvoiding Cardiovascular EventsBlood pressure goalsInitial antihypertensive therapyInitial antihypertensive treatmentPrespecified secondary analysisProgression of nephropathySystolic Hypertension (ACCOMPLISH) trialFrequent adverse eventsKidney disease progressionSerum creatinine concentrationTelephone-based interactive voice response systemAntihypertensive therapyAntihypertensive treatmentRenal outcomesCardiovascular morbidity
2008
Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant LM, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. Journal Of The American College Of Cardiology 2008, 51: 1865-1871. PMID: 18466801, DOI: 10.1016/j.jacc.2007.12.050.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBiomarkersBlack or African AmericanCaptoprilFemaleHeart FailureHospitalizationHumansIncidenceMaleMiddle AgedMyocardial InfarctionRetrospective StudiesRisk FactorsSystoleTetrazolesUnited StatesValineValsartanVentricular Dysfunction, LeftWhite PeopleConceptsLeft ventricular systolic dysfunctionHeart failureAcute myocardial infarctionMyocardial infarctionBaseline characteristicsAfrican AmericansMyocardial Infarction ComplicatedAngiotensin receptor blockersCoronary risk factorsOutcomes of patientsRecurrent myocardial infarctionVentricular systolic dysfunctionSimilar clinical outcomesHF hospitalizationCardiovascular morbidityCause mortalityReceptor blockersSystolic dysfunctionVentricular dysfunctionCardiovascular mortalityWhite patientsClinical outcomesPoor outcomeVALIANT trialSubgroup analysis
2007
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk
Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K, Investigators F. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. Blood Pressure 2007, 16: 13-19. PMID: 17453747, DOI: 10.1080/08037050701217643.Peer-Reviewed Original ResearchConceptsBody mass indexHigh cardiovascular riskCardiovascular eventsHypertensive patientsCardiovascular riskDiabetes mellitusCombination therapyNon-fatal cardiovascular endpointsCoronary artery bypass graftMean body mass indexAnti-lipid therapyAvoiding Cardiovascular EventsOral diabetes therapyPrevious antihypertensive treatmentSystolic Hypertension (ACCOMPLISH) trialDouble-blind treatmentAcute coronary syndromeArtery bypass graftAntihypertensive combination therapyHistory of strokePercutaneous coronary interventionAnti-platelet agentsACCOMPLISH trialAntihypertensive treatmentCardiovascular morbidity
2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Investigators F. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal 2005, 150: 323-329. PMID: 16086938, DOI: 10.1016/j.ahj.2004.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug CostsGlobal HealthHealth Care CostsHealth ResourcesHeart FailureHospital CostsHospitalizationHumansMyocardial InfarctionProspective StudiesQuality of LifeTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsQuality of lifeMyocardial infarctionAcute Myocardial Infarction trialLower medication costsMyocardial Infarction trialHealth-related qualityLinear mixed-effects regression analysisMultinational clinical trialsMixed-effects regression analysisCaptopril groupStudy medicationCardiovascular morbidityVentricular dysfunctionMost patientsHeart failureACE inhibitorsMedication costsProspective economic evaluationClinical trialsHigh riskPatientsValsartanResource useCaptoprilSignificant differences
2003
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal Of Medicine 2003, 349: 1893-1906. PMID: 14610160, DOI: 10.1056/nejmoa032292.Peer-Reviewed Original ResearchConceptsCaptopril groupValsartan groupMyocardial infarctionCardiovascular eventsAdverse eventsHeart failureMost drug-related adverse eventsDrug-related adverse eventsLeft ventricular systolic dysfunctionAngiotensin receptor blocker valsartanAngiotensin converting enzyme (ACE) inhibitorsEnd pointMyocardial Infarction ComplicatedNonfatal cardiovascular eventsDouble-blind trialPrimary end pointVentricular systolic dysfunctionComposite end pointLeft ventricular dysfunctionPopulation of patientsACE inhibitor captoprilAcute myocardial infarctionAdditional therapyCardiovascular morbidityRenal dysfunction